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Objectives: This study aimed to adapt the ADPKD Outcomes Model in order to 
compare the Chronic Kidney Disease progression and relative costs of Autosomal 
Dominant Polycystic Kidney Disease (ADPKD)-affected patients treated with JINARC 
as compared to non-treated patients in Italy. MethOds: Utilising the structure 
of the ADPKD Outcomes Model adapted to the Italian context, the analysis has 
simulated the evolution of ADPKD patients over a period of 80 years. The study 
was performed from both the National Health Service and social perspectives. The 
ADPKD Outcomes Model is based on a series of annual simulations at the individual 
patient level that allows clinical evolutions, such as the achievement of end-stage 
renal disease (ESRD). The model is able to incorporate country-specific pathways for 
ESRD-affected patients, such as haemodialysis (HD), peritoneal dialysis (PD), trans-
plant and conservative therapy, together with their different costs and mortality 
rates. Clinical data on treatment effect of tolvaptan were derived from TEMPO 3:4 
clinical trial. Results: The results show that tolvaptan is estimated to postpone the 
time-to-ESRD by a mean of around 3.7 years and increase life expectancy by a mean 
of 1.6 years. It is predicted that a larger number of ESRD events and deaths could 
be avoided among treated patients vs non-treated patients (e.g. 346 ESRD events 
avoided, and 68 deaths for ESRD avoided at 15 years). In addition, the cumulative cost 
per patient treated who reaches ESRD, compared to non-treated patient, generates 
overall savings in the medium to long-term (e.g. at 15 years, € 16.6 million saved for 
HD and € 2.0 million saved for PD). cOnclusiOns: The use of JINARC in ADPKD 
patients permits not only a slowing down in the worsening of the disease, but also 
an increase in life expectancy and the achievement of a considerable decrease in 
direct and indirect health costs in the medium to long-term.
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Objectives: To assess the cost-effectiveness of delayed-release dimethyl fuma-
rate (DMF) versus treatments for relapsing remitting multiple sclerosis (RRMS) 
from a Spanish Health System perspective. MethOds: A decision analytic 
Markov model was developed to assess the cost-effectiveness of DMF versus IFN 
beta (IFNβ )-1a IM, IFNβ -1a 22 and 44 mcg SC, IFNβ -1b SC, glatiramer acetate (GA) 
SC, teriflunomide, fingolimod and natalizumab in RRMS patients. Based on the 
Expanded Disability Status Scale (EDSS), 21 health states were defined (EDSS 0-9 
RRMS, EDSS 0-9 SPMS and death). Disability disease progression rate, relapse rate, 
treatment disutility, adverse events, rates of withdrawal and disease related mor-
tality were assessed over a 30-year period. Data sources included published litera-
ture, clinical trials, Spanish price/tariff lists, and national population statistics. 
Results are presented as quality-adjusted life-years (QALY) and incremental cost 
effectiveness ratio (ICER). Univariate and probabilistic sensitivity analyses were 
performed. Results: DMF showed higher QALYs and lower costs compared to 
IFNβ -1a IM (0.122 QALYs; -2,761€ ), IFNβ -1a 44mcg SC (0.093 QALYs; -8,827€ ), IFNβ -1b 
SC (0.286 QALYs; -7,108€ ), GA SC (0.235 QALYs; -1,040€ ), teriflunomide (0.125 QALYs; 
-260€ ) and fingolimod (0.184 QALYs; -29,813€ ). In the comparison of DMF vs IFNβ -1a 
22 mcg SC, DMF provided incremental QALYs of 0.193 and an anticipated ICER of 
23,482€ . Compared to natalizumab, DMF showed incremental QALYs of -0.143 and 
incremental costs of -29.001€ , being less effective and cheaper. Sensitivity analyses 
demonstrated the robustness of the model. At a decision-maker’s willingness to 
pay of < 30.000€ , DMF was cost-effective in more than 80% of simulations versus 
IFN beta-1a IM, IFNβ -1a 44 mcg SC, IFNIβ -1b SC and GA SC; in 52% of simulations 
versus INFβ -1a 22 mcg SC; in 65% of simulations versus teriflunomide; and in 100% 
of simulations versus fingolimod. cOnclusiOns: In this analysis DMF showed 
dominance in ICER against IFNβ -1a IM, IFNβ -1a 44 mcg SC, IFNβ -1b SC, GA SC, 
teriflunomide and fingolimod.
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Objectives: Congenital Adrenal Hyperplasia (CAH) is one of the core conditions 
for which all states plus D.C. require newborn screening. Yoo and Grosse (2009) 
(Y/G) performed a CEA using a national incidence figure, indicating a lack of cost-
effectiveness for CAH screening (ICER, $292,000/life year gained). However, the 
incidence of the disease varies among the states, which could affect the cost-
effectiveness of the screening. Here we examine variability in that ICER due to 
variation in state incidence. MethOds: We reconstructed a decision tree from Y/G 
to reproduce their deterministic ICER for CAH screening. We then ran the model 
for every state having a record of cases of CAH in the last year we were able to find 
incidence measures for most states (2006) to estimate ICERs by state. Results: 
We were able to approximately reproduce the Y/G result for the ICER ( $293,927 
per life year saved vs. $ 292,000 from Y/G, difference < 1%). After excluding states 
with missing data (5) and states with zero measured 2006 incidence (13), the ICERs 
of the remaining 33 states are shown, as expected, to inversely relate to the state 
incidence. The ICERs ranged from $37,535 (D.C.) to $1,514,018 (Illinois) per life year 
saved (median, $303,555). Three of the 33 states have ICERs less than $150,000 per 
life year. cOnclusiOns: Different incidences of CAH have a clear effect on the 
Y/G ICERs of CAH newborn screening. In contrast to the general results from Y/G, 
using a national average incidence, 3 states have ICERs in a range that indicates 
possible cost-effectiveness in a deterministic model (ICER < $ 150,000), suggest-
ing that a PSA may be an interesting extension to assess the level of uncertainty 
around the state-level ICER estimates.
Pack-size data were sourced from the NHSBA December 2014 Drug Tariff and BNF 
68. A ‘comparable’ drug had the same active ingredient, concentration and admin-
istration method as the prescribed drug. Cost-savings, had the cheapest compa-
rable drugs been prescribed, were calculated as: [total NIC in 2014] – ([total mg of 
prescribed drugs] x [£/mg of cheapest comparable drugs]). The branded cost range, 
had only branded prescribing occurred, was calculated as: [total mg of prescribed 
drugs] x [£/mg of the most or least expensive branded comparable drugs]. Results: 
Actual total NIC for antiepileptics in 2014 was £498,552,273. Had the cheapest com-
parable drug always been prescribed, this would have decreased by £95,853,020. 
The greatest cost-savings would have been in MHRA categories 2 (40%) and 3 (44%). 
Had branded prescribing always occurred, total NIC would have increased between 
£58,988,547 (if cheapest branded drug prescribed) and £86,315,621 (if most expensive 
branded drug prescribed). The greatest increase would have been in MHRA category 
2 (£34,267,393 to £44,191,174). cOnclusiOns: It was estimated that greater branded 
prescribing of antiepileptics would have increased total NIC by between 12% and 
17%. Only prescribing generically could have decreased total NIC by 19%. These 
estimates should be considered in light of increased risk for, and associated cost 
of, therapeutic failure.
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Objectives: To describe relationships among persistency with subcutaneous inter-
feron beta-1a (scIFNβ 1a), relapse timing relative to discontinuation, and medical 
costs in patients with multiple sclerosis (MS). MethOds: Patients (aged 18-63 years) 
with ≥ 1 MS claim (ICD-9-CM:340.xx) and an initial scIFNβ 1a claim (index event), 12 
months of continuous eligibility before and 24 months after index were identified 
in the IMS PharMetrics Plus™ database. Discontinuation was defined as a ≥ 90 day 
gap in scIFNβ 1a therapy. Relapse was defined as the first post-index MS-related 
inpatient stay, emergency room (ER) visit or MS outpatient visit with a corticosteroid 
claim ±7 days. Relapse was categorized as before or after scIFNβ 1a discontinuation. 
Medical costs [excluding disease-modifying drug (DMD) costs] per day (US$) pre or 
post discontinuation of scIFNβ 1a are presented. Costs were evaluated with general-
ized linear regression models using gap, time of first relapse and the interaction 
as predictors. Prior costs, age, gender and time until relapse were evaluated as 
covariates. Results: 1540 MS patients met the study criteria; 29.2% had a relapse 
and 50% (n= 770) discontinued scIFNβ 1a during the follow-up period. Patients dis-
continuing scIFNβ 1a averaged 250 (SD= 182) days of treatment and 33.1% relapsed, 
while those who did not discontinue averaged 726 (SD= 15) days of treatment and 
25.2% relapsed (p< 0.01). Non-DMD medical cost/day was lowest for patients with no 
gap and no relapse ($24.71/day). Patients who discontinued scIFNβ 1a and had their 
first relapse after discontinuation, had non-DMD medical costs of $39.04/day prior 
to discontinuation, and $52.29/day after discontinuation. Patients with no gap and a 
relapse while scIFNβ 1a was available had lower non-DMD medical costs ($38.88/day), 
than patients with a gap in scIFNβ 1a that experienced a relapse while on treatment 
($72.37/day). Models suggest that costs differ depending on gap status and timing 
of the relapse relative to scIFNβ 1a discontinuation (p< 0.01). cOnclusiOns: These 
results suggest the value of maintaining scIFNβ 1a treatment.
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Objectives: To analyze factors of recent evolution of Multiple Sclerosis 
(MS) Disease Modifying Therapies (DMT) budgets in Spain between 2004 and 
2014. MethOds: 2004-2014 single DMT monthly expenditure was provided by IMS 
Health. For each DMT line: (First line: subcutaneous and intramuscular interferon 
(IFN) β -1a, subcutaneous IFN β -1b and glatiramer acetate injection. Second line: 
natalizumab and fingolimod) were calculated monthly and annually evolution of 
number of patients, billing, drug cost per patient and cost per year of treatment. 
Two periods: 2004-2014 and 2007 (start marketing second lines DMT)-2014 period 
were analyzed for each DMT line. Results: During 2004-2014 DMT expenditure 
increased from 115.5M€ to 353.8M€ due to: A greater number of patients 165% 
(10.27% annual growth per year) and a further growth of annual cost per patient: 
15.82% (1.48 % annual growth per year). In December 2014 second lines correspond 
to a 35.63% of DMT expenditure. Annual cost per patient in second line represents 
53% over cost per treated patient and 82% greater than first line DMT cost per 
year. If year 2007 is omitted from analysis (Only 68 second-line treatments and 
1.44M€ of associated expense) and is analyzed 2008-2014 period, second-line DMT 
represent 61% of new treatments causing a 78% increase in DMT expenditure. In 
2014 second line DMT participation reaches 86% of new regimens causing the 
91.23% of increase DMT expenditure. cOnclusiOns: The growing incorporation 
of new therapies and the appreciable rise in the number of treated patients (10.27 
% annual growth per year) are components to consider in the pharmaceutical 
budget management.
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population-based MS survey for relapse rates. A network meta-analysis was con-
ducted to estimate the comparative efficacy of each treatment versus placebo. 
Costs (in 2013 Euro) of drug acquisition, disease management, relapses, and AEs 
were from public databases and literature. Clinical and economic outcomes were 
projected over 30 years and discounted at 3.5% per year. Results: Over 30 years, 
treatment with PEG-IFN resulted in higher QALYs and cost-savings compared 
with all commercially available self-injectable DMTs in Ireland. Deterministic 
sensitivity analyses confirmed the results were robust. Probabilistic sensitivity 
analyses indicated that the incremental cost-effectiveness ratio was below the 
willingness-to-pay threshold (€ 45,000 per QALY) in > 85% of 5,000 replications 
versus all comparators. cOnclusiOns: PEG-IFN is a cost-effective treatment for 
patients with RRMS in Ireland.
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Objectives: Glybera is the first gene therapy drug for lipoprotein lipase deficiency 
(LPLD), which was approved by European Commission in 2012. Before the approval 
of Glybera, no effective treatment was available for LPLD. Patients with LPLD have 
to restrictively control fat intaken and are still more likely to suffer recurrent acute 
pancreatitis and eruptive xanthomas. Although Glybera can effectively improve 
the health conditoin of patients with LPLD, it is still controversial to price the 
gene therapy at 1.1 million euros. This study assesses the relative costs and effec-
tiveness of Glybera compared to no treatment for LPLD from a societal perspec-
tive. MethOds: We developed a Markov model that tracked a cohort of patients 
through the three disease states of LPLD progression, defined by the symptoms of 
pancreatitis. We evaluated the effectiveness of the noval gene therapy based on pub-
lished clinical trial data. We derived quality of life utility scores and costs data for 
each disease state from the published literature. We estimated the discounted costs, 
quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). 
Univariate sensitivity analyses were conducted to assess the impact of param-
eter uncertainty on our results. Results: The incremental cost-effective ratio 
(ICER) of Glybera was € 51,789/QALY gained when compared with no intervention. 
Correspondingly, the net monetary benefit (NMB) is € 667,478, given the willingness-
to-pay (WTP) is € 114,875. One-way sensitivity analyses were performed to investi-
gate the model robustness. The analyses illustrated that the model was robust to 
the majority transition probabilities and utility of each health state. cOnclusiOns: 
Although the price is high, Glybera is a cost-effective treatment for lipoprotein 
lipase deficiency compared with no treatment based on available clinical data. This 
conclusion is robust to sensitivity analyses.
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Objectives: To assess the cost-effectiveness of EGb761® for the treatment of 
mild dementia due to Alzheimer’s disease (AD) and vascular dementia (VaD) 
in the Czech Republic in comparison to no treatment or acetylcholinesterase 
inhibitor (AChEI-donepezil; only AD). MethOds: Developed ten-year Markov 
cohort model with half-year cycle length projects outcomes (Quality-Adjusted 
Life-Years-QALYs; Life-Years Gained-LYGs) and costs of treatment for patients 
with AD and VaD aged 65 years from payers’ perspective. Model health states are 
defined by the severity of dementia according to Mini-Mental State Examination 
(MMSE), i.e. no&minimal/mild/moderate/moderately severe/severe dementia and 
by death. Treatment schemes of dementia, which reflect current management, 
differ depending on severity of disease and assessed interventions. Transition 
probabilities and utilities were taken from published literature. Drug costs 
(EGb761®€ 63/half-year, donepezil € 94/half-year) and costs of mild/moderately 
severe/severe dementia (€ 192/€ 318/€ 1,709 per half-year) were derived based on 
statement of KOLs and reimbursed lists. Costs and outcomes were discounted 
by 3%. Probability sensitivity analysis (PSA; 3,000 iteration) was performed with 
willingness-to-pay (WTP) threshold of 3 times GDP per capita in the Czech Republic 
(i.e. € 44,000). Results: EGb761® was dominant compared to no treatment in both 
mild AD and mild VaD while generating cost savings of € 560 and € 355 and gaining 
0.2150QALYs/0.1287LYGs and 0.1841QALYs/0.11439LYGs over a 10-year horizon. In 
comparison to active therapy in mild AD, EGb761® is slightly less efficient (loss 
of 0.0025QALYs/0.0001LYGs), but also cheaper (by € 35) than AChEI in a 10-year 
horizon. PSA showed that probability of EGb761®to be cost-effective varies from 
50% to 84% at the WTP threshold. cOnclusiOns: EGb761® represents a cost-
saving intervention with more QALY gained, i.e. dominant therapy compared to 
no pharmacotherapy in treatment of mild dementia in 10 years. EGb761® shows 
very similar results (slightly cheaper and less efficient) in comparison to AchEI 
(e.g. donepezil) in the therapy of mild AD.
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Objectives: The objective of this literature review was to explore the exist-
ing evidences regarding cost-effectiveness of interventions used to treat epi-
lepsy. MethOds: A systematic literature review was performed using the PICO 
method: Population was patients suffering from epilepsy; Intervention and 
Comparators were any treatments, including non-pharmacological treatments, and 
Outcomes were ICERs. The literature search was performed with the NHS EED filters 
using MEDLINE, EMBASE and PubMed from January 2005 to May 5th, 2015. Results: 
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Objectives: Self-injectable disease-modifying therapies (DMTs) are the first-line 
standard of care for relapsing-remitting multiple sclerosis (RRMS) in Scotland: 
Interferon beta (IFNβ )-1a (22mcg and 44mcg three times/week, and 30mcg once/
week), IFNβ -1b 250mcg every other day, and glatiramer acetate (GA) 20mg once/
day. Peginterferon beta-1a (PEG-IFN; 125mcg subcutaneous every two weeks) is a 
new DMT with less frequent dosing which may improve treatment adherence. The 
pivotal ADVANCE trial showed benefits of PEG-IFN versus placebo on relapses and 
disability progression, but its long-term clinical and economic consequences ver-
sus other DMTs are still unknown. This analysis assessed the cost-effectiveness of 
PEG-IFN versus self-injectable DMTs from the National Health System perspective 
in Scotland. MethOds: A Markov cohort economic model, published and accepted 
by health technology assessment authorities, was adapted for this analysis. The 
model predicts disability progression (measured by the Expanded Disability Status 
Scale [EDSS]) and occurrence of relapses and other adverse events (AEs), and trans-
lates them into quality-adjusted life-years and costs. The natural history data were 
obtained from the placebo arm of the ADVANCE trial extrapolated with data from 
the London, Ontario database for EDSS transition probabilities and from a large 
population-based MS survey for relapse rates. A network meta-analysis was con-
ducted to estimate the comparative efficacy of each treatment versus placebo. Costs 
(in 2014 British Pounds) of drug acquisition, disease management, relapses, and 
AEs were from public databases and literature. Clinical and economic outcomes 
were projected over 30 years and discounted at 3.5% per year. Results: Over 30 
years, PEG-IFN yielded greater clinical benefits and cost savings compared with 
IFNβ -1a 22mcg IFNβ -1a 30mcg, and IFNβ -1b 250mcg. Compared with GA 20mg and 
IFNβ -1a 44mcg, the incremental cost-effectiveness ratios were £17,821 and £4,121, 
respectively. Deterministic and probabilistic sensitivity analyses confirmed that 
the results were robust. cOnclusiOns: PEG-IFN is a cost-effective treatment for 
patients with RRMS in Scotland.
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Objectives: Teriflunomide 14 mg is the only first-line DMT with significant reduc-
tion in both relapses and 12-week disability progression in 2 pivotal clinical trials. 
Cost-effectiveness of teriflunomide 14 mg once daily orally vs other first-line DMTs 
for RRMS (oral dimethyl fumarate [DMF] 240 mg twice daily; subcutaneous glatiramer 
acetate (GA) 20 mg daily, interferon ([IFN] β -1a 44 µg 3× /week, and IFNβ -1b 250 µg 
every other day; intramuscular IFNβ -1a 30 µg once weekly) and best supportive care 
(BSC) were evaluated in the Finnish healthcare payer setting. MethOds: The primary 
outcome was incremental cost-effectiveness ratio (ICER; € /quality-adjusted life-year 
[QALY] gained vs nondominated alternatives). Markov cohort modeling with a 20-year 
time horizon (3%/year discount rate) was employed. During each 1-year modeling 
cycle, patients could maintain their Expanded Disability Status Scale (EDSS) score or 
experience progression, develop secondary-progressive MS (SPMS), have EDSS pro-
gression in SPMS, or experience relapse with/without hospitalization or death. Patient 
characteristics, standardized mortality ratios, and an RRMS progression matrix were 
derived from a Finnish MS registry. Specific annual adverse event (AE) risks were 
included. A mixed-treatment comparison informed treatment effects. EQ-5D quality-
of-life estimates and Finnish direct costs were associated with EDSS scores, relapses, 
and AEs. Robustness of base case results was tested with probabilistic sensitivity 
analyses (PSAs). Results: Teriflunomide was less costly with higher QALYs vs GA and 
IFNs. DMF brought marginally more QALYs than teriflunomide (0.129 over 20 years); 
this difference was associated with higher costs. The ICER for DMF vs teriflunomide 
was 78,092, and teriflunomide had the lowest ICER of 17,326 vs BSC. In the PSAs, 
teriflunomide had over 50% cost-effectiveness probabilities, with willingness-to-pay 
values below € 94,000/QALY gained vs other first-line DMTs. cOnclusiOns: The cost-
effectiveness of teriflunomide 14 mg once daily vs DMF twice daily and dominance 
over other first-line DMTs for RRMS were demonstrated in this Finnish study.
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Objectives: Peginterferon beta-1a (PEG-IFN; 125mcg subcutaneous every 2 weeks) 
is a new disease-modifying therapy (DMT) for relapsing-remitting multiple scle-
rosis (RRMS) that may improve treatment adherence by reducing the frequency 
of administration. The pivotal ADVANCE trial showed benefits of PEG-IFN versus 
placebo on relapses and disability progression, but its long-term clinical and eco-
nomic consequences versus other DMTs are still unknown. This analysis assessed 
the cost-effectiveness of PEG-IFN versus other self-injectable DMTs (Interferon 
beta-1a 22mcg and 44mcg three times/week, and 30mcg once/week; interferon 
beta-1b 250mcg every other day; and glatiramer acetate 20mg once/day) from the 
Health Services Executive perspective in Ireland. MethOds: An economic model, 
using a Markov cohort approach, published and accepted by health technology 
assessment authorities, was adapted for this analysis. The model predicts dis-
ability progression (measured by the Expanded Disability Status Scale [EDSS]) 
and occurrence of relapses and other adverse events (AEs), and translates them 
into quality-adjusted life-years (QALYs) and costs. Natural history data were 
obtained from the placebo arm of the ADVANCE trial extrapolated with data from 
the London, Ontario database for EDSS transition probabilities and from a large 
